Q-omics provides the consensus-scored MIR1285-1 profile across patient tissues and cancer cell-line models. MIR1285-1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR1285-1 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, MIR1285-1 RNA expression shows 18,598 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, BRCA, and THYM as cancer lineages where MIR1285-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1285-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1285-1 survival associations across molecular data types. MIR1285-1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1285-1 RNA expression–survival associations across cancer types. High MIR1285-1 expression shows unfavorable associations in KIRC, STAD and PRAD, but favorable associations in UCS, LUAD and ACC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR1285-1 RNA expression.
This table summarizes MIR1285-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1285-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1285-1 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, PAAD, BLCA and CHOL. The BRCA box plot shows higher MIR1285-1 RNA expression in normal versus tumor tissue (log2 FC = −0.853, t-test p < 0.001).
This table shows molecular features associated with MIR1285-1 in patient tissues and cancer cell lines. In patient samples, MIR1285-1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
